Abstract
Cancer treatments are developing fast and the number of cancer survivors could arise to 20 million in United State by 2025. However, a large fraction of cancer survivors demonstrate cognitive dysfunction and associated decreased quality of life both shortly, and often long-term, after chemotherapy treatment. The etiologies of chemotherapy induced cognitive impairment (CICI) are complicated, made more so by the fact that many anti-cancer drugs cannot cross the blood-brain barrier (BBB). Multiple related factors and confounders lead to difficulties in determining the underlying mechanisms. Chemotherapy induced, oxidative stress-mediated tumor necrosis factor-alpha (TNF-α) elevation was considered as one of the main candidate mechanisms underlying CICI. Doxorubicin (Dox) is a prototypical reactive oxygen species (ROS)-generating chemotherapeutic agent used to treat solid tumors and lymphomas as part of multi-drug chemotherapeutic regimens. We previously reported that peripheral Dox-administration leads to plasma protein damage and elevation of TNF-α in plasma and brain of mice. In the present study, we used TNF-α null (TNFKO) mice to investigate the role of TNF-α in Dox-induced, oxidative stress-mediated alterations in brain. We report that Dox-induced oxidative stress in brain is ameliorated and brain mitochondrial function assessed by the Seahorse-determined oxygen consumption rate (OCR) is preserved in brains of TNFKO mice. Further, we show that Dox-decreased the level of hippocampal choline-containing compounds and brain phospholipases activity are partially protected in TNFKO group in MRS study. Our results provide strong evidence that Dox-targeted mitochondrial damage and levels of brain choline-containing metabolites, as well as phospholipases changes decreased in the CNS are associated with oxidative stress mediated by TNF-α. These results are consistent with the notion that oxidative stress and elevated TNF-α in brain underlie the damage to mitochondria and other pathological changes that lead to CICI. The results are discussed with reference to our identifying a potential therapeutic target to protect against cognitive problems after chemotherapy.
Original language | English |
---|---|
Pages (from-to) | 1-8 |
Number of pages | 8 |
Journal | Free Radical Biology and Medicine |
Volume | 134 |
DOIs | |
State | Published - Apr 2019 |
Bibliographical note
Funding Information:We thank the Redox Metabolism Shared Resource Facility of the NCI-designated Markey Cancer Center and its associated CCSG grant, 2 P30 CA177558-06 for the OCR results. This work was supported in part by a Multiple PI R01 grant to DAB, D.S.C., and S.B. [R01 CA217934-02].
Publisher Copyright:
© 2018 Elsevier Inc.
Keywords
- Chemotherapy-induced cognitive impairment
- Doxorubicin
- MRS
- Mitochondrial dysfunction
- Oxidative stress
- Phospholipases
- Tumor necrosis factor-alpha
ASJC Scopus subject areas
- Biochemistry
- Physiology (medical)